ACRV vs. OGI, IVA, TELO, ATOS, LFCR, IXHL, ZVRA, GALT, GLSI, and TRVI
Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Organigram (OGI), Inventiva (IVA), Telomir Pharmaceuticals (TELO), Atossa Therapeutics (ATOS), Lifecore Biomedical (LFCR), Incannex Healthcare (IXHL), Zevra Therapeutics (ZVRA), Galectin Therapeutics (GALT), Greenwich LifeSciences (GLSI), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical preparations" industry.
Acrivon Therapeutics (NASDAQ:ACRV) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.
Acrivon Therapeutics has a net margin of 0.00% compared to Organigram's net margin of -188.38%. Organigram's return on equity of -40.19% beat Acrivon Therapeutics' return on equity.
71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 34.6% of Organigram shares are held by institutional investors. 7.3% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 0.1% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Acrivon Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
In the previous week, Acrivon Therapeutics had 1 more articles in the media than Organigram. MarketBeat recorded 16 mentions for Acrivon Therapeutics and 15 mentions for Organigram. Acrivon Therapeutics' average media sentiment score of 0.78 beat Organigram's score of 0.33 indicating that Acrivon Therapeutics is being referred to more favorably in the media.
Organigram received 172 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 96.15% of users gave Acrivon Therapeutics an outperform vote while only 70.61% of users gave Organigram an outperform vote.
Acrivon Therapeutics has higher earnings, but lower revenue than Organigram. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Acrivon Therapeutics presently has a consensus target price of $22.88, indicating a potential upside of 157.31%. Given Acrivon Therapeutics' higher possible upside, equities analysts plainly believe Acrivon Therapeutics is more favorable than Organigram.
Summary
Acrivon Therapeutics beats Organigram on 10 of the 17 factors compared between the two stocks.
Get Acrivon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acrivon Therapeutics Competitors List
Related Companies and Tools
